Home / Stock ratings / SANA
Stock rating · Biological Products, (No Diagnostic Substances)
Sana Biotechnology, Inc. (SANA) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Sana Biotechnology, Inc. 57 out of 100 (Promising). Its highest factor score is analyst sentiment at 95, and its lowest is price momentum at 21.
MELANY ratingRated 2026-10-06SANA · composite score
About Sana Biotechnology, Inc.
Sana Biotechnology Inc is a biotechnology company that develops engineered cells as medicines and therapies. Its cell engineering programs span several therapeutic areas with unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disease, and central nervous system (CNS) disorders, with a candidate pipeline that includes SC291, SC262, UP421, and others.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why SANA scores 57/100
SANA's 8 factor scores run from 21 to 95, and 3 of them sit above its composite of 57. Here is how SANA breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Earnings in 30 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Analyst targets 199% upside
- Institutional net buying +7.7%
Near-term events that could move the stock.
- Earnings in 30 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How SANA compares
As of October 7, 2026, Sana Biotechnology, Inc. ranks 9th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 65.
Key risks for SANA
- Short interest 23% of float, high volatility risk on news
- Weak price momentum, trend not yet confirmed, may need more time to set up
- High beta 2.2, amplifies market drawdowns 1.8x+ in selloffs
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Sana Biotechnology, Inc. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds SANA's momentum and catalyst factors above.
SANA trade plan (Pro)
MELANY has a full position plan for Sana Biotechnology, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates SANA
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Sana Biotechnology, Inc.'s 57/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about SANA
Is Sana Biotechnology, Inc. (SANA) a buy?
As of 2026-10-06, MELANY rated Sana Biotechnology, Inc. Promising with a composite score of 57/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Sana Biotechnology, Inc.'s MELANY score?
Sana Biotechnology, Inc. (SANA) has a MELANY composite score of 57/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the SANA stock rating calculated?
MELANY scores SANA from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Sana Biotechnology, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Sana Biotechnology, Inc. (SANA) Promising with a composite of 57/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the SANA stock price forecast?
MELANY does not publish price targets or forecasts for SANA. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 57/100 across eight factors for Sana Biotechnology, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is SANA stock overvalued or undervalued?
MELANY's valuation factor currently reads 61/100 for Sana Biotechnology, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives SANA's read.
What price should I buy SANA at?
Rather than chasing the current price, MELANY computes a smart entry zone for SANA: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying SANA stock?
The top risks MELANY currently flags for Sana Biotechnology, Inc.: Short interest 23% of float, high volatility risk on news; Weak price momentum, trend not yet confirmed, may need more time to set up; High beta 2.2, amplifies market drawdowns 1.8x+ in selloffs; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Sana Biotechnology, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 24/100 for Sana Biotechnology, Inc., and earnings track record, at 50/100. The 57/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will SANA stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 21/100 for SANA right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this SANA rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores SANA continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, SANA included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.